The trial, known as NRG-CC009, was designed to answer a deceptively simple question. Stereotactic radiosurgery delivers highly focused, ablative doses of radiation to individual metastases while sparing surrounding healthy brain tissue, whereas whole-brain radiotherapy treats the entire organ, including regions responsible for memory, language, and executive function. In tumors such as lung adenocarcinoma, breast cancer, and melanoma, randomized studies have repeatedly shown that radiosurgery better preserves neurocognitive function and quality of life without compromising survival. Small cell lung cancer, however, carries a reputation for diffuse, aggressive seeding of the central nervous system, and clinicians have long worried that treating only visible lesions with radiosurgery would leave microscopic disease to flourish, producing widespread intracranial progression and worse neurological outcomes. NRG-CC009 was built to test that assumption directly.

Investigators enrolled 151 eligible patients with brain metastases arising from small cell lung cancer and randomized them in a one-to-one fashion between stereotactic radiosurgery alone and hippocampal-avoidant whole-brain radiotherapy delivered with memantine. The hippocampal-avoidant technique, which shapes the radiation beams to reduce dose to the memory-critical hippocampi, combined with the neuroprotective drug memantine, represents the most refined version of whole-brain therapy currently available, making the comparison a rigorous test of the best modern standard against the focused alternative. Patients were stratified by disease-specific graded prognostic assessment score and by the number of brain metastases, and baseline characteristics were well balanced across the two arms. The median number of brain metastases was two, with a range extending from one to twenty-six and an interquartile range of one to five, capturing the broad spectrum of disease burden seen in clinical practice.

The primary endpoint of the trial was time to neurocognitive failure, a measure that reflects when patients experience clinically meaningful decline on standardized testing of cognitive performance. With 91 events, the study was powered at 85 percent to detect a 17 percent absolute reduction in neurocognitive failure between the arms, assuming a rate of death without failure of 29.8 percent in both groups, using a two-sided type I error of 0.05. Secondary endpoints included overall survival, intracranial disease progression, neurological death, the use of salvage therapies, and adverse events. This statistical architecture mattered, because the trial was explicitly designed to determine whether radiosurgery could deliver the cognitive protection seen in other tumor histologies, or whether the biology of small cell lung cancer would erase that advantage.

The answer on the primary endpoint was negative. At a median follow-up of 9.5 months for surviving patients, there was no significant difference in the time to neurocognitive failure between the two treatment approaches, with a Gray’s test p-value of 0.66 and an adjusted hazard ratio for the radiosurgery arm of 0.83, corresponding to a 95 percent confidence interval of 0.53 to 1.28 and a p-value of 0.39. In other words, radiosurgery did not significantly improve cognitive outcomes compared with hippocampal-avoidant whole-brain radiotherapy, and the trial therefore failed to meet its primary endpoint. For a field accustomed to radiosurgery demonstrating clear cognitive superiority, the finding is a striking reminder that tumor biology can override assumptions imported from other disease settings.

Yet the survival data told a very different and unexpected story. Overall survival was superior in the stereotactic radiosurgery arm, with a median of 17.4 months compared with 8.6 months for patients receiving hippocampal-avoidant whole-brain radiotherapy. The adjusted hazard ratio for the radiosurgery arm was 0.60, with a 95 percent confidence interval of 0.39 to 0.91 and a p-value of 0.016, indicating a statistically significant and clinically substantial survival advantage. In a disease where median survival after brain metastasis diagnosis has historically been measured in months, a near-doubling of median survival represents an outcome of genuine clinical consequence, and one that emerged from a trial designed primarily to measure cognition rather than survival.

Equally important was what the trial did not find. Adjusted analyses showed no differences between the arms in intracranial failure, neurological mortality, salvage therapy use, or treatment-related grade 3 to 5 adverse events. The central fear that has kept radiosurgery out of small cell lung cancer, namely that sparing the whole brain would invite diffuse central nervous system progression, was not borne out by the data. Chad Rusthoven, MD, of the University of Colorado Anschutz and lead author of the NRG-CC009 abstract, addressed this concern directly, noting that one of the fundamental worries about upfront radiosurgery alone for small cell lung cancer was that patients might develop diffuse central nervous system progression leading to worse neurological and survival outcomes, but that this was not what the trial observed. Although there were no differences in neurocognitive failure, treatment with radiosurgery was associated with superior overall survival compared with hippocampal-avoidant whole-brain radiotherapy, findings he said support radiosurgery as a reasonable standard of care option for patients with small cell lung cancer brain metastases.

The implications for clinical practice are considerable. Vinai Gondi, MD, of Northwestern University Feinberg School of Medicine and lead Principal Investigator of the trial, emphasized that NRG-CC009 provides results that will help physicians better counsel their patients on treatment approaches for small cell lung cancer brain metastases, adding that the overall survival difference is an important factor to be discussed with patients. For decades, the conversation between oncologist and patient has been framed around a single accepted option; these results introduce a genuine alternative that appears at least as safe and potentially more effective in extending life. The finding that cognitive outcomes were comparable, rather than worse with radiosurgery, removes the principal theoretical objection to adopting the focused approach, while the survival signal provides an affirmative reason to prefer it in appropriately selected patients.

Caution and nuance remain essential. The trial did not meet its primary endpoint, and the survival benefit, while statistically significant, arose in a study of 151 patients with a median follow-up of 9.5 months, so longer observation and broader datasets will be needed to confirm the magnitude and durability of the survival difference. The phrase appropriately selected patients also matters, since the trial stratified patients by prognostic score and metastasis number, and the range of disease burden was wide. Clinicians will need to weigh individual factors, including the number and location of lesions, the extent of systemic disease control, and patient preferences, when choosing between the two strategies. Salvage therapy patterns, neurological death rates, and toxicity profiles were comparable, which suggests that neither approach carries an obvious safety penalty, but the decision will increasingly become one of shared judgment rather than default practice.

What NRG-CC009 ultimately demonstrates is the power of inclusive trial design. Small cell lung cancer patients were excluded from the studies that defined modern brain metastasis management, and the field filled the resulting evidence vacuum with assumption rather than data. By finally testing the question directly, the NRG Oncology investigators have shown that one of those assumptions, the uniquely diffuse and unforgiving nature of small cell lung cancer in the brain, may not justify a whole-brain treatment paradigm at all. The trial was supported by grants from the National Cancer Institute, including U10CA180822, UG1CA189867, U24CA180803, and multiple supplemental awards, and the findings were presented by a collaboration whose legacy programs, the Radiation Therapy Oncology Group among them, have shaped radiation oncology for half a century. For patients with small cell lung cancer and brain metastases, a disease long defined by limited options and guarded prognoses, the message from Boston is quietly transformative: the focused beam, long reserved for other cancers, may now belong to them as well.

Subject of Research: A Phase III trial comparing stereotactic radiosurgery with hippocampal-avoidant whole-brain radiotherapy for brain metastases from small cell lung cancer

Article Title: NRG Oncology Trial Finds No Difference in NeurocoNRG Oncology trial finds no difference in neurocognitive outcomes, but improved overall survival with stereotactic radiosurgery for SCLC brain metastases

Article References: NRG Oncology Trial Finds No Difference in NeurocoNRG Oncology trial finds no difference in neurocognitive outcomes, but improved overall survival with stereotactic radiosurgery for SCLC brain metastases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: stereotactic radiosurgery, whole-brain radiotherapy, small cell lung cancer, brain metastases, NRG-CC009, neurocognitive outcomes, overall survival, hippocampal avoidance, memantine, radiation oncology, clinical trial, ASTRO 2026